Mankind Pharma reports 55% YoY growth in PAT for Q3 FY24
Revenue from Operations stood at Rs. 2,607 crore, 25% YoY growth. Domestic revenue at Rs. 2,400 crore, 20% YoY growth and export revenue at Rs. 207 crore, 118% YoY growth
Revenue from Operations stood at Rs. 2,607 crore, 25% YoY growth. Domestic revenue at Rs. 2,400 crore, 20% YoY growth and export revenue at Rs. 207 crore, 118% YoY growth
This is the first and only oral once-a-day therapy for testosterone suppression in patients with advanced prostate cancer in India
Exblifeb demonstrates remarkable efficacy in treating complicated Urinary Tract Infections (cUTI), pneumonia
About 75% of all primary liver cancers in adults are HCC and up to 30% of HCC patients are eligible for embolisation
Union Ayush Minister with Assam Chief Minister lays foundation stone for Central Research Institute of Yoga & Naturopathy
Combines biocompatibility, heat-resistance, transparency and durability
Pivotal trial found the enfortumab vedotin plus pembrolizumab combination significantly extended overall and progression-free survival
The initiative is a response to the rising incidents of heart attacks and cardiac arrests in the state
The company will be preferred business partner for VPPL in terms of sourcing and supplying key raw materials
Subscribe To Our Newsletter & Stay Updated